We are joined by Ivan Kairatov, a biopharma expert with deep insights into the intricate world of drug research and development. In our conversation, we’ll explore the high-stakes landscape of regulatory approvals, touching on Bristol Myers Squibb's pivotal new cancer therapy, the challenging path
The persistent search for a long and healthy life has often prioritized cardiovascular fitness, yet a groundbreaking study suggests a more fundamental measure of vitality might be found in something as simple as the strength of your grip. This new body of research illuminates a powerful,
In the intricate and often relentless world of oncology, a recent discovery has illuminated a previously hidden pathway that governs the very genesis of a deadly blood cancer, suggesting that the key to halting the disease might lie within a mechanism once thought to be part of the problem. This
In the high-stakes world of pharmaceutical development, a successful Phase 3 trial is typically a cause for celebration, yet Ocular Therapeutix's recent announcement for its wet AMD treatment, Axpaxli, was met with a starkly different reality. The drug achieved its primary endpoint with statistical
With a major breakthrough in psychedelic medicine, Compass Pathways' psilocybin-based therapy, COMP360, has delivered compelling Phase 3 results, sending shockwaves through the biopharma world and reigniting hope for patients with treatment-resistant depression. To unpack what this means for
The aftermath of a spinal cord injury unleashes a devastating and prolonged biological assault, where the secondary damage cascade often proves more destructive than the initial physical trauma. This secondary injury process is a complex storm of excessive reactive oxygen species, relentless
